PolitiKit

Work with the various government programs that support accessibility, inclusion, and a world without barriers, particularly in the built environment around an accessibility Certification Program which will assess and rate the built environment of Canada against a common standard (example Canadian Standards Association).

Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.

Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB).

Free trade agreements as they relate to the biopharmaceutical industry.

Free trade agreements as they relate to the biopharmaceutical industry

Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)

Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time to reimbursement and streamline federal/provincial listing processes.

Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework.

Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

Any and all free trade treaty agreements as it relates to the North American Free Trade Agreement (NAFTA) and trade negotiations between Canada as it relates to the European Union, India, Japan and the Trans-Pacific Partnership. International trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.

Communication regarding free trade agreements as they relate to the biopharmaceutical industry.

Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.

Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

Canada's Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework

Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)

Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector

Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.

Free Trade agreements as they relate to the biopharmaceutical industry

Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.

"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans."

Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities

Comprehensive disability income programs, with respect to persons with MS and other chronic and episodic disabilities

Federal Budget: Allocate funding for the Canada Disability Benefit, the Employment Insurance Sickness Benefit; health research; access to treatment and care; and other budgetary policy as it relates to MS.

Home care, with respect to creation with provincial/ territorial governments programs relating to increased home care for persons with MS and other disabilities/ diseases and the support of caregivers

We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).

Access to treatments as it relates to the current regulatory and price negotiation processes to enhance timely access to all Health Canada approved MS disease-modifying therapies, with respect to the National Strategy for Drugs for Rare Diseases and national pharmacare.

Canada Health Act and regulations, as it relates to long-term and home care

Discussing ways in which to financially support, but not limited to, access to recreation for children, teens, and young adults and for under-served communities, in support of healthy active living, obesity and chronic disease reduction and prevention strategies

Canada-EU Trade Agreement, CUSMA, CPTTP and Canada-UK. The components within these agreements that we are interested in are agriculture and protection/exemption of supply management.

In the context of dairy farming, enhancing the availability of veterinary medical technologies and analyzing the implications of the ongoing Health Canada consultation.

Développement durable - Représentations auprès du gouvernement du Canada afin qu'il soutienne les investissements en recherche, transfert et innovation de manière à favoriser la mise en place d'initiatives structurantes en matière de développement durable permettant d'assurer la pérennité et la résilience des fermes laitières.

Maintien et protection de la gestion de l'offre - Représentations afin que le gouvernement du Canada n'accorde aucun accès supplémentaire au marché laitier intérieur dans un accord commercial permanent avec le Royaume-Uni ou dans tout autre accord commercial, y compris le MERCOSUR, l'Alliance pacifique ou le PTPGP

Développement durable - Représentations auprès du gouvernement du Canada afin de développer conjointement, avec les instances provinciales, un programme soutenant les investissements requis qui permettront aux fermes laitières canadiennes de mettre en œuvre le Code de pratiques pour le soin et la manipulation des bovins laitiers.

Maintien et protection de la gestion de l'offre - Représentations auprès du Gouvernement du Canada afin qu'il protège et défende son droit souverain pour déterminer et administrer ses propres politiques nationales telles que celles ayant une incidence sur la gestion de l'offre, y compris l'attribution des contingents tarifaires dans le cadre du PTPGP et de l'ACEUM.

Démarches visant à obtenir un financement pour soutenir et consolider une production pharmaceutique locale et robuste au Canada.

Advocacy to enhance support for university research mobilization and commercialization activities.

Canada Pension Plan – Disability with respect to eligibility for persons with MS and other chronic and episodic disabilities

Comprehensive disability income programs, with respect to persons with MS and other chronic and episodic disabilities

Federal Budget: Allocate funding for the Canada Disability Benefit, the Employment Insurance Sickness Benefit; health research; access to treatment and care; and other budgetary policy as it relates to MS.

We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).

Home care, with respect to creation with provincial/ territorial governments programs relating to increased home care for persons with MS and other disabilities/ diseases and the support of caregivers

Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities

Bill C-64, An Act Respecting Pharmacare with respect for persons with MS and other chronic conditions and disabilities

Access to treatments as it relates to the current regulatory and price negotiation processes to enhance timely access to all Health Canada approved MS disease-modifying therapies, with respect to the National Strategy for Drugs for Rare Diseases and national pharmacare.

Canada Health Act and regulations, as it relates to long-term and home care

Amendments to immigration policies, regulations, and legislation that would help to remove barriers to foreign trained physicians practicing in Canada and inter-provincial barriers.

Working with federal partners to streamline Health Canada policies and processes related to clinical trials and drug authorization specific to children.

Supporting the introduction and passing of legislation that would increase protections for children and youth online.

Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.

Canada-United States-Mexico Agreement (CUSMA) and pharmaceutical intellectual property protection.

Incentives and programs to attract and support manufacturing activities in Canada

Development of Health Emergency Readiness Canada agency, and role in promoting development life sciences sector.

Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy

Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement

Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.

The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.

Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy

Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.

Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods

INTELLECTUAL PROPERTY/PATENT POLICY AND REGULATIONS in respect of creating Canada as one of the world's most competitive jurisdictions in protecting IP (e.g., match level of European Union via CETA negotiations)